Valuation dashboard for Halozyme Therapeutics, Inc. (HALO) with P/E 30.18, P/B 86.81, EV/EBITDA N/A and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20).
Analysis Summary
Halozyme Therapeutics, Inc. reported revenue of $1.40B in the most recent fiscal year, growing at a 5-year CAGR of 39.2%. Net income reached $316.9M, with a 19.7% 5-year CAGR.
Trailing-twelve-month margins: gross margin 78.2%, operating margin 56.8%, net margin 24.9%.
Balance sheet quality for HALO: current ratio of 4.7. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 30.18 |
| Price / Book | 86.81 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $93.08 |
| vs Current Price | -13.0% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| HALO | Halozyme Therapeutics, Inc. | $12.7B | 30.18 | 86.81 | |
| JAZZ | Jazz Pharmaceuticals plc | $15.5B | 15.84 | 3.17 | 21.4% |
| HSIC | Henry Schein, Inc. | $9.9B | 25.08 | 3.12 | 12.4% |
| ABVX | Abivax S.A. | $7.5B | 15.11 | -73.9% | |
| CYTK | Cytokinetics, Incorporated | $9.1B | 119.0% | ||
| GRFS | Grifols, S.A. | $6.5B | 14.21 | 1.17 | |
| CAI | Caris Life Sciences, Inc. | $8.0B | 85.99 | 15.29 | 18.8% |
| CORT | Corcept Therapeutics Incorporated | $12.1B | 207.35 | 16.10 | 8.4% |
Price
| Price | $106.99 |
| Market Cap | $12.7B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Gross Margin | 78.18% |
| Operating Margin | 56.77% |
| Net Margin | 24.86% |
Related companies: ABVX · ATR · CAI · CORT · CYTK · GRFS · HSIC
Explore sector: Healthcare · Biotechnology
More sections of HALO: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks